PRECLINICAL AND CLINICAL PHARMACOLOGY/EXPERIMENTAL THERAPEUTICS

“需要采取创新战略， 腺癌患者的预后 胃肠道我们正在研究调节性的相互作用 细胞毒药物与氟尿嘧啶在体外确定最佳 用于潜在临床用途的序列。研究旨在 阐明最佳的管理时间表和机制， 具有抗结肠癌细胞系活性的新药物对 促进其合理的临床应用。我们实施临床试验， 结合临床药代动力学、生物化学和/或分子 端点。开发了新的分析测定方法来测量 的药代动力学和细胞内药效学 抗癌剂。我们的目标是开发新的代理商和药物 联合治疗胃肠道癌症患者，并制定策略 选择性靶向具有基因组不稳定性的癌细胞， 程序性细胞死亡途径受损"

"Innovative strategies are needed to improve the prognosis of patients with adenocarcinomas arising in the gastrointestinal tract. We are studying the interaction of modulatory & cytotoxic agents with fluorouracil in vitro to define optimal sequences for potential clinical use. Studies are designed to elucidate the optimal schedule of administration & mechanism of action of novel agents with activity against colon cancer cell lines to facilitate their rational clinical use. We implement clinical trials that incorporate clinical pharmacokinetic, biochemical &/or molecular endpoints. New analytic assay methods are developed to measure the pharmacokinetics & intracellular pharmacodynamics of the anticancer agents. Our goal is to develop new agents & drug combinations for patients with GI cancers, & to develop strategies that selectively target cancer cells with genomic instability &/or impaired programmed cell death pathways."